Inhibition of the signal transducer and activator of transcription 3 signaling pathway by Qianliening capsules suppresses the growth and induces the apoptosis of human prostate cells

Lin,Jiumao; Zhou,Jianheng; Zhong,Xiaoyong; Hong,Zhenfeng; Peng,Jun

doi:10.3892/mmr.2014.2946

Inhibition of the signal transducer and activator of transcription 3 signaling pathway by Qianliening capsules suppresses the growth and induces the apoptosis of human prostate cells

Authors:
- Jiumao Lin
- Jianheng Zhou
- Xiaoyong Zhong
- Zhenfeng Hong
- Jun Peng
View Affiliations

Affiliations: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: November 13, 2014 https://doi.org/10.3892/mmr.2014.2946
Pages: 2207-2214

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The signal transducer and activator of transcription 3 (STAT3) pathway is one of the main growth factor‑mediated signal transduction pathways and is closely associated with the occurrence and development of benign prostatic hyperplasia (BPH). Qianliening capsules (QC) have significant therapeutic effects on BPH; however, the precise mechanism underlying its anti‑BPH activity remains to be elucidated. To further elucidate the molecular mechanism of the therapeutic effect of QC on BPH, the present study used epidermal growth factor (EGF), which has a role in the pathogenesis of BPH, to stimulate the growth of human prostate WPMY‑1 cells and activate the STAT3 pathway in the WPMY‑1 cells. The cell viability was determined using an MTT assay and the cell morphology was observed by phase‑contrast microscopy. Fluorescence activated cell sorting analysis with Annexin‑V/propidium iodide (PI) staining and PI staining were performed to examine cell apoptosis and the cell cycle. The activation of caspase‑9 and ‑3 were evaluated by colorimetric assay. STAT3 phosphorylation and transcriptional activity were detected by western blot analysis and the luciferase gene reporter, respectively. The mRNA and protein expression levels of B‑cell lymhoma 2 (Bcl‑2), Bcl‑2‑associated X protein (Bax), cyclin D1, cyclin‑dependent kinase 4 (CDK4) and p21 were measured by reverse transcription quantitative polymerase chain reaction and western blot analysis, respectively. In the present study, QC was found to significantly and dose‑dependently inhibit the EGF‑stimulated growth of WPMY‑1 cells, as evidenced by QC‑induced cell morphological changes and a reduction in cell viability. In addition, QC treatment markedly induced the activation of caspase‑9 and ‑3. QC treatment also inhibited the EGF‑mediated increase of STAT3 phosphorylation levels and transcriptional activity in WPMY‑19 cells, accompanied by downregulation of the expression of Bcl‑2, cyclin D1 and CDK4 and upregulation of the expression of Bax and p21. These results suggested that QC effectively inhibited the proliferation and promoted the apoptosis of human prostate cells via modulation of the STAT3 signaling pathway and its target genes, which is likely to be one of the mechanisms underlying its activity in BPH treatment.

View Figures

View References

1	Sirab N, Robert G, Fasolo V, et al: Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes inbenign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 14:14301–14320. 2013. View Article : Google Scholar : PubMed/NCBI
2	Atawia RT, Tadros MG, Khalifa AE, Mosli HA and Abdel-Naim AB: Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats. Toxicol Lett. 219:160–169. 2013. View Article : Google Scholar : PubMed/NCBI
3	Pollan MC, Benghuzzi HA and Tucci M: Growth factor expression in early stages of benign prostatic hyperplasia upon exposure to sustained delivery of androgens. Biomed Sci Instrum. 39:329–334. 2003.PubMed/NCBI
4	Paolone DR: Benign prostatic hyperplasia. Clin Geriatr Med. 26:223–239. 2010. View Article : Google Scholar : PubMed/NCBI
5	Roehrborn CG: Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 95:87–100. 2011. View Article : Google Scholar
6	Gat Y, Gornish M, Heiblum M and Joshua S: Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment. Andrologia. 40:273–281. 2008. View Article : Google Scholar : PubMed/NCBI
7	Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol. 153:1085–1096. 1995. View Article : Google Scholar : PubMed/NCBI
8	Wang Z and Olumi AF: Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation. 82:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
9	Descazeaud A, Weinbreck N, Robert G, et al: Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int. 108:E23–E28. 2011. View Article : Google Scholar
10	Voss M, Trojan L, Steidler A, et al: Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia. Anal Quant Cytol Histol. 30:199–202. 2008.PubMed/NCBI
11	Ma Z, Tsuchiya N, Yuasa T, et al: Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 123:2574–2579. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang W, Zhang X, Mize GJ and Takayama TK: Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia. Prostate. 68:1064–1075. 2008. View Article : Google Scholar : PubMed/NCBI
13	Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
14	Siejka A, Schally AV, Block NL and Barabutis N: Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate. 70:1087–1093. 2010. View Article : Google Scholar : PubMed/NCBI
15	Siejka A, Schally AV, Block NL and Barabutis N: Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 106:1382–1388. 2010. View Article : Google Scholar : PubMed/NCBI
16	Lin JM, Zhou JH, Xu W, et al: Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway. Exp Ther Med. 5:1293–1300. 2013.PubMed/NCBI
17	Lin J, Hong Z, Zhou H, et al: Expression of the growth factor related to angiogenesis on the prostatic hyperplasia in rats. J Fujian Univ Tradit Chin Med. 18:63–65. 2008.(In Chinese).
18	bin Jia, Hong Tang, Weimin Li and Wenqing Cai: The effects of epidermal growth factor on the expression of Bcl-2, Bax and c-myc in mice prostate cells. Chin J Gerontol. 27:251–252. 2007.(In Chinese).
19	Park OK, Schaefer TS and Nathans D: In vitro activation of STAT3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA. 93:13704–13708. 1996. View Article : Google Scholar : PubMed/NCBI
20	Zhong Z, Wen Z and Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
21	Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
22	Karni R, Jove R and Levitzki A: Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 18:4654–4662. 1999. View Article : Google Scholar : PubMed/NCBI
23	Coqueret O and Gascan H: Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J Biol Chem. 275:18794–18800. 2000. View Article : Google Scholar : PubMed/NCBI
24	Bienvenu F, Gascan H and Coqueret O: Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. J Biol Chem. 276:16840–16847. 2001. View Article : Google Scholar : PubMed/NCBI
25	Huang YP, Du J, Hong ZF, et al: Effects of Kangquan recipe on sex steroids and cell proliferation in rats with benign prostatic hyperplasia. Chin J Integr Med. 15:289–292. 2009. View Article : Google Scholar : PubMed/NCBI
26	Boyle P, Robertson C, Lowe F and Roehrborn C: Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 55:533–539. 2000. View Article : Google Scholar : PubMed/NCBI
27	Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al: Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon) in benign prostatic hyperplasia. Prostate. 45:259–266. 2000. View Article : Google Scholar : PubMed/NCBI
28	Quiles MT, Arbós MA, Fraga A, et al: Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Prostate. 70:1044–1053. 2010. View Article : Google Scholar : PubMed/NCBI
29	Lin JM, Huang YP, Zhou Jh and Hong ZF: Therapeutic efficacy of Qianliening capsules in the treatment of benign prostatic hyperplasia. Asia-Pacific Traditional Medicine. 9:140–143. 2013.(In Chinese).
30	Zhou J, Lin J, Xu W, et al: Qianliening capsule treats benign prostatic hyperplasia through regulating the expression of sex hormones, estrogen receptor and androgen receptor. Afr J Pharm and Pharmacol. 6:173–180. 2012. View Article : Google Scholar
31	Zhong X, Lin J, Zhou J, et al: Qianliening capsule treats benign prostatic hyperplasia (BPH) by down-regulating the expression of PCNA, CyclinD1 and CDK4. Afr J Biotechnol. 11:7731–7737. 2012.
32	Zheng HY, Xu W, Lin JM, Peng J and Hong ZF: Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis. Mol Med Rep. 7:848–854. 2013.PubMed/NCBI
33	Hong ZF, Lin JM, Zhong XY, et al: Qianliening capsule inhibits human prostate cell growth via induction of the mitochondrion-dependent cell apoptosis. Chin J Integr Med. 18:824–830. 2012. View Article : Google Scholar : PubMed/NCBI
34	Lin JM, Chen YQ, Cai QY, et al: Scutellaria barbata D Don inhibits colorectal cancer growth via suppression of multiple signaling pathways. Integr Cancer Ther. 13:240–248. 2014. View Article : Google Scholar
35	Lin JM, Chen YQ, Wei LH, et al: Ursolic acid promotes colorectal cancer cell apoptosis and inhibits cell proliferation via modulation of multiple signaling pathways. Inter J Oncol. 43:1235–1243. 2013.
36	Roehrborn CG, Nuckolls JG, Wei JT, et al: The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int. 100:813–819. 2007. View Article : Google Scholar : PubMed/NCBI
37	Black L, Naslund MJ, Gilbert TD Jr, Davis EA and Ollendorf DA: An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care. 12:S99–S110. 2006.PubMed/NCBI
38	Roehrborn C, Boyle P, Nickel JC, Hoefner K and Andriole G: ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60:434–441. 2002. View Article : Google Scholar : PubMed/NCBI
39	Roderick MacDonald and Wilt Timothy J: Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effects. Urology. 66:780–788. 2005. View Article : Google Scholar
40	Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar
41	Verma V, Sharma V, Singh V, et al: Labda-8(17),12,14-trien-19-oic acid contained in fruits of Cupressus sempervirens suppresses benign prostatic hyperplasia in rat and in vitro human models through inhibition of androgen and STAT-3 signaling. Phytother Res. 28:1196–203. 2014. View Article : Google Scholar : PubMed/NCBI